All Stories

  1. Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience

    Article • Pharmaceutics, March 2024, MDPI AG

    Szabolcs Szatmari

  2. Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson’s disease patients

    Article • Scientific Reports, February 2024, Springer Science + Business Media

    Szabolcs Szatmari

  3. A Rare Case of Histopathologically Confirmed Creutzfeldt–Jakob Disease from Romania, Long Route to Diagnosis—Case Report and an Overview of the Romanian CJD Situation

    Article • Journal of Clinical Medicine, August 2022, MDPI AG

    Szabolcs Szatmari

  4. Az intestinalis gél bevezetésekor rögzített jellemzők tízéves változásai előrehaladott Parkinson-kóros betegekben

    Article • Orvosi Hetilap, July 2022, Akademiai Kiado

    Szabolcs Szatmari

  5. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience

    Article • Pharmaceutics, May 2022, MDPI AG

    Szabolcs Szatmari

  6. Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial

    Article • EClinicalMedicine, February 2022, Elsevier

    Szabolcs Szatmari

  7. Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease

    Article • Brain Sciences, June 2021, MDPI AG

    Szabolcs Szatmari

  8. Döntési szempontok és az eszközös terápia elfogadásához szükséges idő előrehaladott Parkinson-kórban

    Article • Orvosi Hetilap, May 2021, Akademiai Kiado

    Szabolcs Szatmari

  9. Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial

    Article • Stroke and Vascular Neurology, November 2020, BMJ

    Szabolcs Szatmari

  10. A gastrointestinalis panaszok felmérésének jelentősége előrehaladott Parkinson-kórban

    Article • Orvosi Hetilap, September 2020, Akademiai Kiado

    Szabolcs Szatmari

  11. Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients

    Article • July 2020, Taylor & Francis

    Szabolcs Szatmari

  12. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke

    Article • Neurology, December 2019, Wolters Kluwer Health

    Szabolcs Szatmari

  13. Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients

    Article • November 2019, Taylor & Francis

    MD, PhD Jozsef Attila Szasz, LIGIA BANCU, Szabolcs Szatmari

  14. Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients

    Article • April 2019, Dove Medical Press

    Szabolcs Szatmari, MD, PhD Jozsef Attila Szasz

  15. Characteristics of levodopa treatment in advanced Parkinson’s disease

    Article • Orvosi Hetilap, April 2019, Akademiai Kiado

    Szabolcs Szatmari, MD, PhD Jozsef Attila Szasz

  16. It is safe to use transdermal glyceryl trinitrate to lower blood pressure in patients with acute ischaemic stroke with carotid stenosis

    Article • Stroke and Vascular Neurology, March 2019, BMJ

    Szabolcs Szatmari

  17. Effect of Glyceryl Trinitrate on Hemodynamics in Acute Stroke

    Article • Stroke, February 2019, Wolters Kluwer Health

    Szabolcs Szatmari

  18. DOPAMINE AGONISTS IN PARKINSON’S DISEASE THERAPY – 15 YEARS OF EXPERIENCE

    Article • Ideggyógyászati Szemle, January 2019, Ideggyogyaszati Szemle Journal

    MD, PhD Jozsef Attila Szasz, Szabolcs Szatmari

  19. Central adjudication of serious adverse events did not affect trial’s safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial

    Article • PLoS ONE, November 2018, PLOS

    Mr Peter John Godolphin, Szabolcs Szatmari

  20. Selective monoamine oxidase B inhibitors for Parkinson's disease in Tirgu Mures, Romania

    Article • Orvosi Hetilap, December 2017, Akademiai Kiado

    Szabolcs Szatmari, MD, PhD Jozsef Attila Szasz

  21. Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial

    Article • Translational Stroke Research, August 2017, Springer Science + Business Media

    Szabolcs Szatmari

  22. Diabetes, dementia, depresszió, distressz

    Article • Ideggyógyászati Szemle, January 2017, Ideggyogyaszati Szemle Journal

    Szabolcs Szatmari

  23. Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial

    Article • Journal of Stroke and Cerebrovascular Diseases, May 2016, Elsevier

    Szabolcs Szatmari

  24. COMPARISON OF HOSPITALIZED ACUTE STROKE PATIENTS’ CHARACTERISTICS USING TWO LARGE CENTRAL-EASTERN EUROPEAN DATABASES

    Article • Ideggyógyászati Szemle, January 2016, Ideggyogyaszati Szemle Journal

    Szabolcs Szatmari

  25. Glyceryl Trinitrate for Acute Intracerebral Hemorrhage

    Article • Stroke, January 2016, Wolters Kluwer Health

    Szabolcs Szatmari

  26. The role of ultrasound in the diagnosis of temporal arteritis

    Article • Neurologia i Neurochirurgia Polska, March 2015, VM Media SP. zo.o VM Group SK

    Szabolcs Szatmari

  27. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial

    Article • The Lancet, February 2015, Elsevier

    Szabolcs Szatmari, Dr William D Strain

  28. Baseline Characteristics of the 4011 Patients Recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial

    Article • International Journal of Stroke, July 2014, SAGE Publications

    Szabolcs Szatmari

  29. Prestroke Alcohol Consumption and Smoking Are Not Associated with Stroke Severity, Disability at Discharge, and Case Fatality

    Article • Journal of Stroke and Cerebrovascular Diseases, January 2014, Elsevier

    MD, PhD Jozsef Attila Szasz, Szabolcs Szatmari

  30. Common Carotid Artery Occlusion: A Case Series

    Article • ISRN Neurology, September 2013, Hindawi Publishing Corporation

    Szabolcs Szatmari

  31. Procaine treatments for cognition and dementia — A Cochrane review

    Article • Journal of the Neurological Sciences, August 2009, Elsevier

    Szabolcs Szatmari

  32. Treatment of dementia and cognitive impairment: What can we learn from the Cochrane Library

    Article • Journal of the Neurological Sciences, August 2009, Elsevier

    Szabolcs Szatmari

  33. Procaine treatments for cognition and dementia

    Article • Cochrane Database of Systematic Reviews, October 2008, Wiley

    Szabolcs Szatmari

  34. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison

    Article • European Journal of Neurology, November 2006, Wiley

    MD, PhD Jozsef Attila Szasz, Szabolcs Szatmari

  35. Mannitol Use in Acute Stroke

    Article • Stroke, July 2003, Wolters Kluwer Health

    Szabolcs Szatmari

  36. Vinpocetine for cognitive impairment and dementia

    Article • Cochrane Database of Systematic Reviews, January 2003, Wiley

    Szabolcs Szatmari

  37. Subcortical features and cognitive performance in Hungarian cerebrovascular outpatients

    Article • Journal of the Neurological Sciences, November 2002, Elsevier

    Szabolcs Szatmari

  38. The Mures-Uzhgorod-Debrecen study: a comparison of hospital stroke services in Central-Eastern Europe

    Article • European Journal of Neurology, May 2002, Wiley

    MD, PhD Jozsef Attila Szasz, Szabolcs Szatmari

  39. Screening of vascular cognitive impairment on a Hungarian cohort

    Article • Psychiatry and Clinical Neurosciences, February 1999, Wiley

    Szabolcs Szatmari